BOSTON--(BUSINESS WIRE)--MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, has appointed Martin J. Driscoll to its Board of Directors, effective immediately.
Mr. Driscoll has more than 30 years of experience in the biopharmaceutical industry. Since November 2010, he has served as president and Chief Executive Officer of Asmacure Ltée, which is focused on the development of small molecule cholinergic receptor modulators for the treatment of pulmonary diseases. Previously, he was the CEO of Javelin Pharmaceuticals, a company focused on the development of acute care pain products. Mr. Driscoll led a successful M&A effort at Javelin culminating in the sale of the company to Hospira, Inc. in July 2010. Earlier in his career, he spent 18 years at Schering-Plough, where he held various global general management positions, including leadership of the company’s largest division, Key Pharmaceuticals. Following his tenure at Schering-Plough, Mr. Driscoll held senior management positions at ViroPharma and Reliant Pharmaceuticals. He also co-founded Pear Tree Pharmaceuticals, a privately held developer of women’s healthcare products. Mr. Driscoll holds a B.Sc. in communications from the University of Texas at Austin.
Mr. Driscoll said, “I believe MetaStat’s development of innovative new tests for the prediction of systemic metastasis represents a bold and important step forward in this area of medicine. I look forward to working with the rest of the Board to maximize the healthcare community’s awareness of these tests and their significance for doctors and breast cancer patients.”
Oscar Bronsther, M.D., Chief Executive Officer of MetaStat, said, “Martin Driscoll brings a tremendous amount of industry experience to MetaStat, and we are truly privileged to have him serve on our Board. We intend to draw heavily on his professional insights as we move toward the commercialization of our MetaSite Breast™ and MenaCalc™ tests.”
About MetaStat, Inc.
MetaStat, Inc. (MTST) is a molecular diagnostic company that develops and commercializes diagnostic tests for early and reliable prediction of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where systemic metastasis is responsible for approximately 90% of all deaths. The company’s function-based diagnostic platform technology is based on the identification and understanding of the pivotal role of the mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both the MetaSite Breast™ and MenaCalc™ assays are designed to accurately stratify patients based on their individual risk of metastasis and to provide physicians with clinically actionable information to better "customize" cancer treatment. MetaStat’s testing platform improves treatment planning decisions by positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. The company is based in Boston.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.